NCT02559856View on ClinicalTrials.gov

Comparison of Bleeding Risk Between Rivaroxaban and Apixaban: The Pilot Study

PHASE4CompletedINTERVENTIONAL
Enrollment

72

Participants

Timeline

Start Date

May 31, 2016

Primary Completion Date

November 30, 2017

Study Completion Date

February 28, 2018

Conditions
Venous Thromboembolism
Interventions
DRUG

Apixaban

DRUG

Rivaroxaban

Trial Locations (4)

T6G 2G3

University of Alberta, Edmonton

L8L 2X2

Hamilton General Hospital, Hamilton

K1H 8L6

The Ottawa Hospital - General Campus, Ottawa

J1G 2E8

Hôtel-Dieu de Sherbrooke, Sherbrooke

Sponsors
All Listed Sponsors
collaborator

Canadian Institutes of Health Research (CIHR)

OTHER_GOV

collaborator

Canadian Venous Thromboembolism Clinical Trials and Outcomes Research (CanVECTOR) Network

NETWORK

lead

Ottawa Hospital Research Institute

OTHER